Literature DB >> 28385779

Role of miR-15a/miR-16-1 and the TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia.

Enrica Rampazzo1, Engin Bojnik1, Livio Trentin2, Laura Bonaldi3, Paola Del Bianco3, Federica Frezzato2, Andrea Visentin2, Monica Facco2, Gianpietro Semenzato2, Anita De Rossi4,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28385779      PMCID： PMC5566049          DOI： 10.3324/haematol.2016.157669

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.

Authors:  Enrica Rampazzo; Laura Bonaldi; Livio Trentin; Carlo Visco; Sonia Keppel; Silvia Giunco; Federica Frezzato; Monica Facco; Elisabetta Novella; Ilaria Giaretta; Paola Del Bianco; Gianpietro Semenzato; Anita De Rossi
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 2.  Telomere/telomerase interplay in virus-driven and virus-independent lymphomagenesis: pathogenic and clinical implications.

Authors:  Riccardo Dolcetti; Anita De Rossi
Journal:  Med Res Rev       Date:  2010-06-14       Impact factor: 12.944

3.  Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro.

Authors:  H Li; Y Cao; M C Berndt; J W Funder; J P Liu
Journal:  Oncogene       Date:  1999-11-18       Impact factor: 9.867

Review 4.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

Review 5.  Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.

Authors:  Chadi Nabhan; Gordana Raca; Y Lynn Wang
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

6.  Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia.

Authors:  Mirjam Hoxha; Sonia Fabris; Luca Agnelli; Valentina Bollati; Giovanna Cutrona; Serena Matis; Anna Grazia Recchia; Massimo Gentile; Agostino Cortelezzi; Fortunato Morabito; Pier Alberto Bertazzi; Manlio Ferrarini; Antonino Neri
Journal:  Genes Chromosomes Cancer       Date:  2014-04-04       Impact factor: 5.006

7.  Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia.

Authors:  Marzia Palma; Anton Parker; Mohammad Hojjat-Farsangi; Jade Forster; Parviz Kokhaei; Lotta Hansson; Anders Osterborg; Håkan Mellstedt
Journal:  Exp Hematol       Date:  2013-03-30       Impact factor: 3.084

8.  Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells.

Authors:  D Xu; Q Wang; A Gruber; M Björkholm; Z Chen; A Zaid; G Selivanova; C Peterson; K G Wiman; P Pisa
Journal:  Oncogene       Date:  2000-10-26       Impact factor: 9.867

Review 9.  MicroRNAs.

Authors:  Muller Fabbri; Carlo M Croce; George A Calin
Journal:  Cancer J       Date:  2008 Jan-Feb       Impact factor: 3.360

10.  Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome.

Authors:  L Terrin; L Trentin; M Degan; I Corradini; R Bertorelle; P Carli; N Maschio; M D Bo; F Noventa; V Gattei; G Semenzato; A De Rossi
Journal:  Leukemia       Date:  2007-03-08       Impact factor: 11.528
View more
  7 in total

Review 1.  Mechanism of Human Telomerase Reverse Transcriptase (hTERT) Regulation and Clinical Impacts in Leukemia.

Authors:  Mot Yee Yik; Adam Azlan; Yaashini Rajasegaran; Aliaa Rosli; Narazah Mohd Yusoff; Emmanuel Jairaj Moses
Journal:  Genes (Basel)       Date:  2021-07-30       Impact factor: 4.096

2.  The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients.

Authors:  Enrica Rampazzo; Paola Del Bianco; Roberta Bertorelle; Caterina Boso; Alessandro Perin; Giovanna Spiro; Francesca Bergamo; Claudio Belluco; Angela Buonadonna; Elisa Palazzari; Sara Lonardi; Antonino De Paoli; Salvatore Pucciarelli; Anita De Rossi
Journal:  Br J Cancer       Date:  2018-02-15       Impact factor: 7.640

3.  The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.

Authors:  Andrea Visentin; Laura Bonaldi; Gian Matteo Rigolin; Francesca Romana Mauro; Annalisa Martines; Federica Frezzato; Silvia Imbergamo; Edoardo Scomazzon; Stefano Pravato; Maria Antonella Bardi; Maurizio Cavallari; Eleonora Volta; Francesco Cavazzini; Maurizio Nanni; Ilaria Del Giudice; Monica Facco; Anna Guarini; Gianpietro Semenzato; Robin Foà; Antonio Cuneo; Livio Trentin
Journal:  Br J Cancer       Date:  2019-06-18       Impact factor: 7.640

Review 4.  MicroRNAs: Tiny Regulators of Gene Expression with Pivotal Roles in Normal B-Cell Development and B-Cell Chronic Lymphocytic Leukemia.

Authors:  Katerina Katsaraki; Paraskevi Karousi; Pinelopi I Artemaki; Andreas Scorilas; Vasiliki Pappa; Christos K Kontos; Sotirios G Papageorgiou
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

Review 5.  Current Implications of microRNAs in Genome Stability and Stress Responses of Ovarian Cancer.

Authors:  Arkadiusz Gajek; Patrycja Gralewska; Agnieszka Marczak; Aneta Rogalska
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

Review 6.  Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets.

Authors:  Giacomo Andreani; Giovanna Carrà; Marcello Francesco Lingua; Beatrice Maffeo; Mara Brancaccio; Riccardo Taulli; Alessandro Morotti
Journal:  Cancers (Basel)       Date:  2020-03-09       Impact factor: 6.639

Review 7.  Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia.

Authors:  Felice Pepe; Veronica Balatti
Journal:  J Clin Med       Date:  2020-02-21       Impact factor: 4.241
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.